Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLPG NASDAQ:HRMY NASDAQ:PRTA NASDAQ:SAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLPGGalapagos$33.27+1.4%$29.30$22.36▼$33.86$2.16B0.07363,440 shs393,201 shsHRMYHarmony Biosciences$35.48+0.1%$34.07$26.47▼$41.61$2.04B0.83551,480 shs506,065 shsPRTAProthena$6.88-0.7%$5.94$4.32▼$24.10$373.02M0.01741,098 shs1.24 million shsSAGESage Therapeutics$8.68-0.2%$8.25$4.62▼$11.44$544.80M0.292.72 million shs22.69 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLPGGalapagos+1.37%-0.06%+18.86%+24.23%+20.33%HRMYHarmony Biosciences+0.08%-4.67%+12.28%+18.82%+4.75%PRTAProthena-0.72%+1.78%+13.34%-21.10%-70.26%SAGESage Therapeutics-0.23%-1.03%-4.82%+16.04%-19.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGLPGGalapagos0.4548 of 5 stars0.84.00.00.02.00.00.6HRMYHarmony Biosciences4.7791 of 5 stars4.51.00.00.03.53.34.4PRTAProthena3.6194 of 5 stars4.24.00.00.01.91.71.3SAGESage Therapeutics3.5013 of 5 stars2.04.00.04.12.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLPGGalapagos 1.50Reduce$25.33-23.86% DownsideHRMYHarmony Biosciences 3.00Buy$51.0043.74% UpsidePRTAProthena 2.33Hold$31.50357.85% UpsideSAGESage Therapeutics 1.93Reduce$8.02-7.66% DownsideCurrent Analyst Ratings BreakdownLatest PRTA, GLPG, SAGE, and HRMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2025HRMYHarmony BiosciencesTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$48.007/10/2025HRMYHarmony BiosciencesDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $55.007/10/2025HRMYHarmony BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$33.007/8/2025SAGESage TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$12.00 ➝ $9.206/20/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral6/20/2025SAGESage TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$7.00 ➝ $9.006/17/2025SAGESage TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$9.00 ➝ $8.506/17/2025SAGESage TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetHold ➝ Hold$8.00 ➝ $9.006/17/2025SAGESage TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$12.006/17/2025SAGESage TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$8.00 ➝ $8.506/16/2025SAGESage TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 7/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLPGGalapagos$275.61M7.96$0.74 per share45.20$47.57 per share0.70HRMYHarmony Biosciences$714.73M2.85$2.95 per share12.03$11.56 per share3.07PRTAProthena$135.16M2.74N/AN/A$9.05 per share0.76SAGESage Therapeutics$41.24M13.18N/AN/A$7.60 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLPGGalapagos$80.16MN/A0.00N/AN/AN/AN/AN/AN/AHRMYHarmony Biosciences$145.49M$2.6213.5411.410.4620.53%24.32%15.92%8/5/2025 (Estimated)PRTAProthena-$122.31M-$2.08N/AN/AN/A-79.94%-21.61%-19.32%8/4/2025 (Estimated)SAGESage Therapeutics-$400.67M-$5.80N/AN/AN/A-747.63%-68.99%-60.67%N/ALatest PRTA, GLPG, SAGE, and HRMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025HRMYHarmony Biosciences$0.78N/AN/AN/A$204.37 millionN/A8/4/2025Q2 2025PRTAProthena-$1.06N/AN/AN/A$5.36 millionN/A7/30/2025Q2 2025SAGESage Therapeutics-$0.96-$0.79+$0.17-$0.79$16.69 million$31.66 million5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million5/6/2025Q1 2025HRMYHarmony Biosciences$0.59$0.78+$0.19$0.78$184.26 million$184.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGLPGGalapagosN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLPGGalapagosN/A8.087.99HRMYHarmony Biosciences0.223.673.63PRTAProthenaN/A9.009.00SAGESage TherapeuticsN/A9.139.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLPGGalapagos32.46%HRMYHarmony Biosciences86.23%PRTAProthena97.08%SAGESage Therapeutics99.22%Insider OwnershipCompanyInsider OwnershipGLPGGalapagos2.91%HRMYHarmony Biosciences23.60%PRTAProthena9.20%SAGESage Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLPGGalapagos1,31065.90 millionN/AOptionableHRMYHarmony Biosciences20057.42 million43.87 millionOptionablePRTAProthena13053.83 million48.88 millionOptionableSAGESage Therapeutics69062.62 million59.18 millionOptionablePRTA, GLPG, SAGE, and HRMY HeadlinesRecent News About These CompaniesSage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of "Reduce" from Brokerages4 hours ago | marketbeat.comSage Therapeutics Announces Second Quarter 2025 Financial Results5 hours ago | finance.yahoo.comSage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue EstimatesJuly 30 at 6:16 PM | zacks.comSage Therapeutics (NASDAQ:SAGE) Sees Strong Trading Volume - Time to Buy?July 30 at 1:16 PM | marketbeat.comMonaco Asset Management SAM Takes $3.51 Million Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)July 30 at 5:38 AM | marketbeat.comSage Therapeutics (SAGE) to Release Quarterly Earnings on WednesdayJuly 28 at 3:48 AM | americanbankingnews.comCerity Partners LLC Purchases New Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)July 27, 2025 | marketbeat.comBML Capital Management LLC Buys New Shares in Sage Therapeutics, Inc. (NASDAQ:SAGE)July 26, 2025 | marketbeat.comEurope's CHMP gives thumbs up to Lilly's Kisunla and Gilead's long-acting PrEP drug YeytuoJuly 25, 2025 | fiercepharma.comFCwm LLC Acquires 58,410 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)July 25, 2025 | marketbeat.comSage Therapeutics (SAGE) Expected to Announce Earnings on WednesdayJuly 23, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Sees Large Volume Increase - What's Next?July 22, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Shares Pass Above Fifty Day Moving Average - Should You Sell?July 16, 2025 | marketbeat.comSAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGEJuly 14, 2025 | businesswire.comBeyond The Numbers: 6 Analysts Discuss Sage Therapeutics StockJuly 9, 2025 | nasdaq.comScotiabank Downgrades Sage Therapeutics (SAGE)July 9, 2025 | msn.comScotiabank Reiterates "Sector Perform" Rating for Sage Therapeutics (NASDAQ:SAGE)July 8, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Takes $347,000 Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)July 8, 2025 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of "Hold" from AnalystsJuly 6, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Share Price Passes Above Two Hundred Day Moving Average - Here's WhyJuly 4, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Shares Pass Above 50 Day Moving Average - Here's WhyJuly 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRTA, GLPG, SAGE, and HRMY Company DescriptionsGalapagos NASDAQ:GLPG$33.27 +0.45 (+1.37%) Closing price 07/30/2025 04:00 PM EasternExtended Trading$32.83 -0.44 (-1.32%) As of 06:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Harmony Biosciences NASDAQ:HRMY$35.48 +0.03 (+0.08%) Closing price 07/30/2025 04:00 PM EasternExtended Trading$35.48 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Prothena NASDAQ:PRTA$6.88 -0.05 (-0.72%) Closing price 07/30/2025 04:00 PM EasternExtended Trading$7.20 +0.32 (+4.65%) As of 07:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.Sage Therapeutics NASDAQ:SAGE$8.68 -0.02 (-0.23%) Closing price 07/30/2025 04:00 PM EasternExtended Trading$8.69 +0.01 (+0.07%) As of 07/30/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How Marvell Went From Short Target to Breakout Star Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic? Palo Alto Networks: The All‑in‑One Cybersecurity Powerhouse Why Lyft’s Stock Volume Just Spiked—Is an EV Partnership Near? NVIDIA: A Major Indicator Just Flashed Sell, But Should You? ChargePoint Recalibrates: What’s Really Under the Hood RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead? Why Billions Are Flowing into IBIT, BlackRock's Bitcoin ETF Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
